Shots:

• The approval is based on the P-III GEMINI 1 & 2 studies to evaluate the efficacy, safety, and tolerability of Vuity vs PBO in a ratio (1:1) in 750 patients aged 40 to 55yrs. with presbyopia
• The studies met its 1EPs i.e., improvement in near vision in low light (mesopic) conditions without impacting distance vision on 30 at 3hrs., improvement was observed as early as 15min. through 6hrs. The therapy was safe, well-tolerated, and effective for managing age-related blurry near vision & no serious AEs were observed in both studies
• Vuity (pilocarpine HCI ophthalmic solution) is the first FDA-approved eye drop to treat a progressive eye condition

Click here to­ read full press release/ article | Ref: Allergan  | Image: PRNewswire